Privacyvoorkeur

MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.


EHA 2020: Journaal Multipel Myeloom

35 min.

Bekijk hier het MEDtalks EHA-journaal over multipel myeloom. In dit journaal bespreken prof. dr. Sonja Zweegman en dr. Inger Nijhof hun highlights van EHA 2020. 

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

  1. IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL
  2. DEPTH OF RESPONSE TO ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA: INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL
  3. EFFICACY AND TOLERABILITY OF INDUCTION TREATMENT WITH IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN FRAIL NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS – RESULTS OF THE PHASE II HOVON 143 TRIAL
  4. A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
  5. IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS
  6. INTERIM RESULTS FROM THE FIRST PHASE 1 CLINICAL STUDY OF THE B-CELL MATURATION ANTIGEN (BCMA) 2+1 T CELL ENGAGER (TCE) CC-93269 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  7. ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH 1Q21 GAIN: INSIGHTS FROM PHASE 1 AND PHASE 3 STUDIES
  8. ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
  9. SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY 

 

Laatst bewerkt: 05-01-2024

  • Sponsoren

    Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door